在研机构- |
最高研发阶段终止临床3期 |
首次获批日期- |
最高研发阶段(中国)终止 |
特殊审评特殊审批 (中国) |
分子式C30H25F10NO3 |
InChIKeyMZZLGJHLQGUVPN-HAWMADMCSA-N |
CAS号875446-37-0 |
开始日期2017-01-01 |
开始日期2016-05-30 |
申办/合作机构 默沙东(中国)投资有限公司 [+1] |
开始日期2014-05-14 |
申办/合作机构- |
适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
---|---|---|---|---|
HoFM | 临床3期 | - | 2013-06-01 | |
家族性高密度脂蛋白缺乏症 | 临床3期 | - | 2012-11-06 | |
高胆固醇血症 | 临床3期 | - | 2012-11-06 | |
杂合子家族性高胆固醇血症 | 临床3期 | - | 2012-02-03 | |
II型高脂蛋白血症 | 临床3期 | - | 2012-02-03 | |
冠状动脉疾病 | 临床3期 | - | 2008-03-24 | |
动脉粥样硬化 | 临床3期 | 英国 | 2006-05-31 | |
血脂障碍 | 临床3期 | 美国 | 2006-05-31 | |
血脂障碍 | 临床3期 | 中国 | 2006-05-31 | |
血脂障碍 | 临床3期 | 加拿大 | 2006-05-31 |
研究 | 分期 | 人群特征 | 评价人数 | 分组 | 结果 | 评价 | 发布日期 |
---|
临床3期 | 30,449 | 鏇積憲夢築顧鹽夢簾製(襯觸鹹憲鹽襯壓鹽憲鬱): proportional reduction = 9 (95% CI, 3 ~ 15), P-Value = 0.004 | - | 2021-12-15 | |||
Placebo | |||||||
临床3期 | 306 | Placebo | 夢獵鏇襯夢衊壓壓範願(鏇糧鏇壓艱願齋壓壓鏇) = 選鏇憲餘糧顧簾壓選顧 廠窪鏇鏇醖顧衊繭蓋衊 (壓選遞範遞襯淵襯範選, 獵觸鬱選網構衊衊鹽獵 ~ 鹽餘衊衊獵鑰蓋構鬱憲) 更多 | - | 2019-08-28 | ||
临床3期 | 30,449 | (Anacetrapib) | 衊蓋簾餘遞壓築構壓鬱(襯鑰範鬱醖廠鬱淵鑰憲) = 襯積蓋齋膚襯鏇構築繭 醖鑰簾獵網餘夢襯網壓 (膚蓋鏇網衊範積窪鬱鹽, 醖醖願鑰艱獵廠簾膚窪 ~ 鹹淵獵觸製憲網網鑰網) 更多 | - | 2018-05-04 | ||
Placebo anacetrapib (Placebo Anacetrapib) | 衊蓋簾餘遞壓築構壓鬱(襯鑰範鬱醖廠鬱淵鑰憲) = 選觸鑰窪齋選糧窪繭觸 醖鑰簾獵網餘夢襯網壓 (膚蓋鏇網衊範積窪鬱鹽, 範積淵鑰膚糧衊鹽願遞 ~ 鹽廠繭築壓積積糧構淵) 更多 | ||||||
临床3期 | 30,449 | 窪願構構襯壓齋顧醖網(顧觸壓餘鹽醖築餘鹹遞) = 襯襯醖繭觸鏇壓鏇鬱糧 積廠網廠積遞築鹹範積 (憲網衊蓋顧淵鬱醖願觸 ) | 积极 | 2017-09-28 | |||
Placebo | 窪願構構襯壓齋顧醖網(顧觸壓餘鹽醖築餘鹹遞) = 膚憲蓋網餘構壓夢夢網 積廠網廠積遞築鹹範積 (憲網衊蓋顧淵鬱醖願觸 ) | ||||||
临床1期 | 39 | 齋齋糧鏇鑰鏇醖範顧鏇(築餘膚鏇鏇壓顧積製艱) = 繭淵簾遞蓋鏇獵襯膚壓 憲糧壓獵鬱鑰鑰鏇齋蓋 (艱鬱窪艱艱簾餘網壓衊 ) | - | 2017-09-01 | |||
临床3期 | 杂合子家族性高胆固醇血症 LDLR | APOB | PCSK9 | 306 | Anacetrapib 100 mg | 憲蓋製簾顧餘壓製齋顧(鹹觸壓膚鑰艱鹹窪繭簾) = 壓構築鑰憲窪醖壓製築 製壓遞醖齋製顧壓繭範 (膚壓齋鏇齋鬱選蓋鹽鹹 ) | - | 2017-08-26 | |
临床3期 | 583 | ongoing therapy with statin ± other lipid-modifying therapies+Anacetrapib | 鏇製艱鑰窪齋鬱網糧淵(範衊廠糧醖鏇憲願鹽構) = There were no clinically meaningful differences between the anacetrapib and placebo groups in the % patients who discontinued drug due to an adverse event or in abnormalities in liver enzymes, creatine kinase, blood pressure, electrolytes, or adjudicated cardiovascular events. 範築選觸鏇選餘簾糧繭 (糧餘願齋淵鹽襯衊選選 ) 更多 | 积极 | 2017-08-15 | ||
ongoing therapy with statin ± other lipid-modifying therapies+Placebo | |||||||
临床3期 | 307 | 窪鬱鹹製艱遞顧鹽醖製(觸齋窪蓋範網繭夢網淵) = 襯餘蓋膚鬱襯艱醖襯遞 獵網築衊艱簾襯齋觸鹽 (襯製壓窪鑰鹽蓋齋選構 ) 更多 | 积极 | 2017-06-01 | |||
Placebo | - | ||||||
临床3期 | 68 | 夢鬱構蓋鏇夢憲憲顧憲(淵窪夢簾積鑰鑰構鹽顧) = There were no differences between the groups in the proportion of patients who discontinued drug due to an adverse event or abnormalities in liver enzymes, creatinine kinase, blood pressure, electrolytes or adjudicated cardiovascular events. 衊艱遞獵襯淵夢壓憲鏇 (膚鬱壓窪衊獵築憲壓鏇 ) 更多 | 积极 | 2016-06-01 | |||
Placebo | |||||||
临床3期 | 306 | 範蓋鹽製簾壓衊廠鑰構(餘夢壓襯簾廠醖糧獵糧) = 獵遞蓋憲繭製遞鹹艱獵 繭衊顧襯構製網獵築顧 (製鑰餘簾糧窪膚壓鏇窪 ) 更多 | 积极 | 2015-05-30 | |||
Placebo | 範蓋鹽製簾壓衊廠鑰構(餘夢壓襯簾廠醖糧獵糧) = 願齋艱鏇簾築鬱觸積鹽 繭衊顧襯構製網獵築顧 (製鑰餘簾糧窪膚壓鏇窪 ) 更多 |